Elemental Scientific, Inc. (ESI), of Omaha, Nebraska, has acquired Electro Scientific Industries’ laser ablation division.
Elemental Scientific, Inc. (ESI), of Omaha, Nebraska, has acquired Electro Scientific Industries’ laser ablation division. The purchase of the division’s New Wave Research (NWR) line of laser ablation systems increases ESI’s portfolio of sample introduction systems for inductively-coupled plasma–atomic emission spectroscopy (ICP-AES) and inductively-coupled plasma mass spectrometry (ICP-MS) systems in trace and metal analysis.
The newly formed entity Elemental Scientific Lasers, LLC, based in Bozeman, Montana, will operate as a wholly-owned subsidiary of Elemental Scientific, Inc.
The laser ablation line acquired by ESI includes the NWR193, NWR213, NWR266, NWRfemto, and NWRimage laser ablation systems along with a series of compatible automation options.
Sales and marketing manager of the Laser Ablation Division, Ciaran O’Connor, said in a statement, “We’re excited to have the NWR leading laser technology join ESI’s highly respected and successful sample introduction and automation offering for ICP and ICP-MS.”
In another statement, Dan Wiederin, the founder and president of ESI, said, “This acquisition enables us to offer a complete portfolio of sample introduction (liquid and solid) solutions, expand development of ablation techniques, and synergize research and development strengths. We’re delighted to have this technology and the operations-dedicated teams join our company.”
An Interview with AES Mid-Career Award Recipient Jason Dwyer
July 25th 2024Jason Dwyer of the University of Rhode Island has been named the recipient of the American Electrophoresis Society’s Mid-Career Award, which honors exceptional contributions to the field of electrophoresis, microfluidics, and related areas by an individual who is currently in the middle of their career.
Glucose's Impact on Brain Cancer Cells Unveiled Through Raman Imaging
July 25th 2024Researchers have used Raman spectroscopy and chemometric methods to reveal how glucose affects normal and cancerous brain cell metabolism. Their findings highlight specific biomarkers that can distinguish metabolic changes, potentially aiding in cancer research and treatment.